Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.

Lian F, Chen W, Liu Y, Shen L, Fan W, Cui W, Zhao Y, Li J, Wang Y.

J Cancer Res Clin Oncol. 2019 Mar 21. doi: 10.1007/s00432-019-02900-8. [Epub ahead of print]

PMID:
30900154
2.

Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.

Huang B, Zheng J, Yao Z, Fan W, Qiu S, Chen L, Chen J.

World J Urol. 2018 Sep 6. doi: 10.1007/s00345-018-2437-x. [Epub ahead of print]

PMID:
30191393
3.

Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.

Huang B, Wang H, Lin H, Yao Z, Zheng J, Fan W, Qiu S, Chen L, Chen J.

J Cancer Res Clin Oncol. 2019 Feb;145(2):487-494. doi: 10.1007/s00432-018-2811-5. Epub 2018 Dec 11.

PMID:
30539282
4.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

5.

Intravesical gemcitabine for non-muscle invasive bladder cancer.

Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2. Review.

PMID:
22259002
7.

A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.

Sun F, Zhao R, Zhu Y, Cui D, Wang X, Han B, Liang S, Liu H, Sun X, Zhao F, Xu D, Xia S.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1099-1107. doi: 10.1007/s00280-017-3305-x. Epub 2017 Apr 18.

PMID:
28421294
8.

Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study.

Zhang Y, Xie L, Chen T, Xie W, Wu Z, Xu H, Xing C, Sha N, Shen Z, Qie Y, Liu X, Hu H, Wu C.

Onco Targets Ther. 2016 Jan 28;9:605-11. doi: 10.2147/OTT.S99866. eCollection 2016.

9.

Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.

Tae BS, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH.

PLoS One. 2017 Dec 15;12(12):e0189354. doi: 10.1371/journal.pone.0189354. eCollection 2017.

10.
11.

A retrospective comparison of thulium laser en bloc resection of bladder tumor and plasmakinetic transurethral resection of bladder tumor in primary non-muscle invasive bladder cancer.

Li K, Xu Y, Tan M, Xia S, Xu Z, Xu D.

Lasers Med Sci. 2019 Feb;34(1):85-92. doi: 10.1007/s10103-018-2604-8. Epub 2018 Aug 31.

PMID:
30171441
12.

Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence.

Yap SA, Brunson A, Pugashetti N, M P H RDC, Keegan THM, deVere White R, Wun T.

Urol Oncol. 2018 Nov;36(11):498.e1-498.e7. doi: 10.1016/j.urolonc.2018.08.004. Epub 2018 Sep 17.

PMID:
30236855
13.

Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.

Miyake M, Tatsumi Y, Matsumoto H, Nagao K, Matsuyama H, Inamoto T, Azuma H, Yasumoto H, Shiina H, Fujimoto K; Nishinihon Uro-Oncology Collaborative Group.

BJU Int. 2018 May;121(5):764-773. doi: 10.1111/bju.14111. Epub 2018 Jan 21.

PMID:
29281857
14.

Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.

Han KS, You D, Jeong IG, Kwon T, Hong B, Hong JH, Ahn H, Ahn TY, Kim CS.

J Korean Med Sci. 2015 Mar;30(3):252-8. doi: 10.3346/jkms.2015.30.3.252. Epub 2015 Feb 16.

15.

Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.

Tanimoto R, Saika T, Ebara S, Kobayashi Y, Nasu R, Yamada D, Takamoto H, Miyaji Y, Nasu Y, Tsushima T, Kumon H.

World J Urol. 2018 Jun;36(6):889-895. doi: 10.1007/s00345-018-2196-8. Epub 2018 Jan 31.

PMID:
29387931
16.
17.

Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study.

Pirzada MT, Ghauri R, Ahmed MJ, Shah MF, Nasir IU, Siddiqui J, Ahmed I, Mir K.

Cureus. 2017 Jan 5;9(1):e957. doi: 10.7759/cureus.957.

18.

Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.

Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA.

Eur Urol. 2016 Jun;69(6):1046-52. doi: 10.1016/j.eururo.2016.01.006. Epub 2016 Jan 20.

PMID:
26803476
19.

The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.

Onishi T, Sekito S, Shibahara T, Uchida K, Sasaki T.

Scand J Urol. 2018 Oct - Dec;52(5-6):385-388. doi: 10.1080/21681805.2018.1548502. Epub 2019 Jan 10.

PMID:
30628540
20.

Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.

Ding W, Gou Y, Sun C, Xia G, Wang H, Chen Z, Tan J, Xu K, Qiang D.

Urol Oncol. 2014 Jan;32(1):42.e13-9. doi: 10.1016/j.urolonc.2013.05.004.

PMID:
24360660

Supplemental Content

Support Center